EUVIMEDEUVIMED entdecken
Crossref

Every CFTR variant counts – Target-capture based next-generation-sequencing for molecular diagnosis in the German CF Registry

Simone Ahting, Lutz Nährlich, Inka Held, Constance Henn, Angelika Krill, Kerstin Landwehr, Jochen Meister, Susanne Nährig, Anna Nolde, Katharina Remke, Renate Ruppel, Annette Sauer-Heilborn und 8 weitere

Journal of Cystic Fibrosis · 2024

DOI: 10.1016/j.jcf.2023.10.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Simone Ahting und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Genetics, University Medical Center Leipzig, Leipzig, Germany. Electronic address: simone.ahting@medizin.uni-leipzig.de. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Registries, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Vertex Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In times of genotype guided therapy options, a total of 3.2 % of people with CF (pwCF) in the German CF Registry[1] only have one or no CFTR-variant detected after genetic analysis. Additionally, genetic data in the Registry can be documented as free text and can therefore be prone to error. In order to allow the greatest possible amount of pwCF access to modern therapies, we conducted a re-evaluation of free text entries and established a custom-whole-CFTR-locus NGS-approach for all pwCF who remained without genetic confirmation afterwards. METHODS: To this end, we assembled 731 free text variants of 655 pwCF in the German CF Registry. All variants were evaluated using ClinVar, HGMD and CFTR1/2, corrected in the Registries' database and uploaded to ClinVar. PwCF whose diagnosis remained uncertain as well as additional pwCF or pwCFTR-RD that were assembled through a nationwide call for testing of unclear cases were offered genetic analysis. Samples were analysed using a target-capture based NGS-custom-design-panel covering the entire CFTR-locus. RESULTS: Evaluation of free text variants led to the discovery of 43 variants not formerly reported in the context of CF. The Registries' dropdown list was extended by 497 variants and over 500 pwCF were provided with their most up-to-date genotype. Samples of 47 pwCF/pwCFTR-RD were sequenced via NGS with an overall success rate of 61.7 %, resulting in implementation of entire CFTR-genotyping into routine diagnostics. CONCLUSION: Entire CFTR-genotyping can greatly increase the genetic diagnostic rate of pwCF/pwCFTR-RD and should be considered after inconspicuous CFTR screening panels in CFTR-diagnostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorRegistriesHigh-Throughput Nucleotide SequencingHumansGermanyGenetic TestingFemaleMaleGenotypeMutation

Stichwörter der Autor:innen

Cystic fibrosisDiagnosticsGeneticsGenotypingNext-generation-sequencing

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, human

Autor:innen und Institutionen

  • Institute of Human Genetics, University Medical Center Leipzig, Leipzig, Germany. Electronic address: simone.ahting@medizin.uni-leipzig.de.
  • Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany.
  • Pediatric Practice Friesenweg, Cystic Fibrosis Center Altona, Hamburg, Germany.
  • Division of pediatric Pulmonology and Allergology, Hospital for children and adolescents, University Medical Center Leipzig, Leipzig, Germany.
  • Division of Pneumology, University Medical Center Homburg, Homburg/Saar, Germany.
  • Division of Allergology and Pediatric Pneumology, University Children's Hospital Bethel, University Medical Center Ostwestfalen-Lippe, Bielefeld, Germany.

Förderung

  • Vertex Pharmaceuticals Inc

Zitieren

APA

Ahting, S., Nährlich, L., Held, I., Henn, C., Krill, A., Landwehr, K., Meister, J., Nährig, S., Nolde, A., Remke, K., Ruppel, R., Sauer-Heilborn, A., Schebek, M., Schopper, G., Schulte-Hubbert, B., Schwarz, C., Smaczny, C., Wege, S., Hentschel, J., & Registry Working Group of the German CF Registry (2024). Every CFTR variant counts – Target-capture based next-generation-sequencing for molecular diagnosis in the German CF Registry. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.10.009

Vancouver

Ahting S, Nährlich L, Held I, Henn C, Krill A, Landwehr K, et al. Every CFTR variant counts – Target-capture based next-generation-sequencing for molecular diagnosis in the German CF Registry. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2023.10.009

BibTeX
@article{Ahting2024,
  author = {Ahting, Simone and Nährlich, Lutz and Held, Inka and Henn, Constance and Krill, Angelika and Landwehr, Kerstin and Meister, Jochen and Nährig, Susanne and Nolde, Anna and Remke, Katharina and Ruppel, Renate and Sauer-Heilborn, Annette and Schebek, Martin and Schopper, Gudrun and Schulte-Hubbert, Bernhard and Schwarz, Carsten and Smaczny, Christina and Wege, Sabine and Hentschel, Julia and Registry Working Group of the German CF Registry, Registry Working Group of the German CF Registry},
  title = {Every CFTR variant counts – Target-capture based next-generation-sequencing for molecular diagnosis in the German CF Registry},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  doi = {10.1016/j.jcf.2023.10.009}
}
Kostenlos starten →